The efficacy of Dulaglutide for the coronary plaque in patiENts with type 2 diabetes mellitus Evaluated By optical coherence tomography: single-center, randomized, open-label, parallel group study

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2020
INTERVENTION: Dulaglutide 0.75mg/week Standard treatment without GLP‐1 receptor agonist (GLP‐1RA) CONDITION: Coronary artery disease PRIMARY OUTCOME: The change of the Lipid Index calculated by OCT from baseline to treatment evaluation (week 38). INCLUSION CRITERIA:
Epistemonikos ID: a380716bd2b81ac86e660da716ce5f8425bb5a59
First added on: Aug 24, 2024